Market Place
Sourcing Support
Kazia To Present EVT801 Data At Ovarian Cancer Symposium
23 Sep 2024 //
PR NEWSWIRE
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
12 Sep 2024 //
PR NEWSWIRE
Kazia prunes failed cancer trial data set to form path to FDA
11 Jul 2024 //
PR NEWSWIRE
Kazia Nasdaq Extension: 180 Days For Minimum Bid Requirement
23 May 2024 //
PR NEWSWIRE
KAZIA: EVT801 Phase 1 Stage 1 Complete In Advanced Cancer
01 May 2024 //
PR NEWSWIRE
Kazia Reports Early Conclusion of Trial After Reaching Primary Endpoint
21 Feb 2024 //
PR NEWSWIRE
Kazia Continues Board Renewal With Two New Appointments
18 Jan 2024 //
PR NEWSWIRE
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
05 Dec 2023 //
PR NEWSWIRE
Kazia Therapeutics Announces $2 Million Registered Direct Offering
01 Dec 2023 //
PR NEWSWIRE
Kazia Provides Overview Of Paxalisib Related Presentations
21 Nov 2023 //
PR NEWSWIRE
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
20 Nov 2023 //
PR NEWSWIRE
Kazia Announces The Release Of Pnoc022 Clinical Study Abstract
15 Nov 2023 //
PR NEWSWIRE
Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data
10 Nov 2023 //
PR NEWSWIRE
Kazia Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib
01 Nov 2023 //
PR NEWSWIRE
Kazia Announces Clinical Data At Esmo 2023 From Ongoing Phase 1 Evt801 Study
23 Oct 2023 //
PR NEWSWIRE
Kazia Therapeutics Announces Acceptance Of Late-Breaking Abstract of PNOC022
29 Sep 2023 //
PR NEWSWIRE
KAZIA`S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT
06 Jul 2023 //
PR NEWSWIRE
Kazia Launches Collaboration With Qimr Berghofer Medical Research Institute
15 Dec 2022 //
PRNEWSWIRE
Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal
09 Dec 2022 //
ACCESSWIRE
Compelling Preclinical Data For Kazia`S Evt801 Published In Journal
01 Dec 2022 //
PRNEWSWIRE
Kazia Tx Reports Promising Interim Data From Combination Study Of Paxalisib
05 Aug 2022 //
PRNEWSWIRE
Kazia dropped from global umbrella trial to treat brain cancer
01 Aug 2022 //
FIERCEBIOTECH
FDA Awards RPDD To Paxalisib For At/Rt
06 Jul 2022 //
PRNEWSWIRE
FDA Awards ODD To Paxalisib For At/Rt, A Rare Form Of Childhood Brain Cancer
17 Jun 2022 //
PRNEWSWIRE
Kazia Presents Positive Final Data From PII Study Of Paxalisib In Glioblastoma
03 Jun 2022 //
PRNEWSWIRE
Kazia Therapeutics To Present At Bio Ceo Conference
07 Feb 2022 //
PRNEWSWIRE
Kazia reports positive results from Phase II trial of glioblastoma therapy
06 Dec 2021 //
CLINICALTRIALSARENA
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib
04 Dec 2021 //
PRNEWSWIRE
PNOC Study in Childhood Brain Cancer Enrols First Patient
11 Nov 2021 //
PRNEWSWIRE
Kazia`s paxalisib program data garners increased target share price of A$2.83
14 Oct 2021 //
PROACTIVEINVESTORS
Kazia Therapeutics to Present at LD Micro Main Event
06 Oct 2021 //
PRNEWSWIRE
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Conference
10 Sep 2021 //
PRNEWSWIRE
Kazia Calls for Increased Focus Brain Cancer Research this GBM Awareness Day
21 Jul 2021 //
PRNEWSWIRE
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
30 Jun 2021 //
PR NEWSWIRE
Paxalisib Study in CNS Lymphoma Enrols 1st Patient
07 Jun 2021 //
PRNEWSWIRE
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
20 Apr 2021 //
ACCESSWIRE
Kazia Licenses Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3
19 Apr 2021 //
PRNEWSWIRE
Evotec Enters Master Service Agreement with Kazia Therapeutics
19 Apr 2021 //
CONTRACTPHARMA
Kazia Therapeutics to present pharmacokinetic data from Paxalisib Phase II
09 Apr 2021 //
PROACTIVEINVESTOR
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading
29 Mar 2021 //
PRNEWSWIRE
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety
17 Nov 2020 //
PRNEWSWIRE
Kazia Therapeutics completes $25.2 million capital raising
23 Oct 2020 //
PROACTIVEINVESTOR
Kazia Executes Agreement To Commence GBM Agile Pivotal Study
16 Oct 2020 //
BIOSPACE
Kazia & Dana-farber Cancer Institute collaborate For Primary CNS Lymphoma
22 Sep 2020 //
BIOSPACE
US FDA grants orphan drug status to Kazia Therapeutics; paxalisib
24 Aug 2020 //
PHARMABIZ
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Survival
01 Jun 2020 //
PRNEWSWIRE
Kazia`s Paxalisib Shows Positive Overall Survival Signal in PhII Glioblastoma
07 Apr 2020 //
PR NEWSWIRE
